Francesca Ligorio

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 5

Top Topics

Positive Breast Cancer

Epidermal Growth Factor Receptor

Top Venues

Cancer research

This page only lists publications with an associated author ORCID identifier.

Publications

Franca Raucci, Claudio Vernieri, Maira Di Tano, Francesca Ligorio, Olga Blaževitš, Samuel Lazzeri, Anastasiya Shmahala, Giuseppe Fragale, Giulia Salvadori, Gabriele Varano, Stefano Casola, Roberta Buono, Euplio Visco, Filippo G De Braud, Valter Daniel Longo
Cyclic fasting-mimicking diet plus bortezomib and rituximab is an effective treatment for chronic lymphocytic leukemia. Cancer research (2024)
Franca Raucci, Claudio Vernieri, Maira Di Tano, Francesca Ligorio, Olga Blaževitš, Samuel Lazzeri, Anastasiya Shmahala, Giuseppe Fragale, Giulia Salvadori, Gabriele Varano, Stefano Casola, Roberta Buono, Euplio Visco, Filippo G De Braud, Valter Daniel Longo
Cyclic Fasting-Mimicking Diet Plus Bortezomib and Rituximab Is an Effective Treatment for Chronic Lymphocytic Leukemia. Cancer research 84 (7) (2024)
Chiara Fabbroni, Giovanni Fucà, Francesca Ligorio, Elena Fumagalli, Marta Barisella, Paola Collini, Carlo Morosi, Alessandro Gronchi, Angelo Paolo Dei Tos, Paolo Giovanni Casali, Roberta Sanfilippo
Impact of Pathological Stratification on the Clinical Outcomes of Advanced Well-Differentiated/Dedifferentiated Liposarcoma Treated with Trabectedin. Cancers 13 (6) (2021)
Francesca Ligorio, Giovanni Fucà, Emma Zattarin, Riccardo Lobefaro, Luca Zambelli, Rita Leporati, Carmen Rea, Gabriella Mariani, Giulia V Bianchi, Giuseppe Capri, Filippo de Braud, Claudio Vernieri
The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab. Cancers 13 (8) (2021)
Serenella Maria Pupa, Francesca Ligorio, Valeria Cancila, Alma Franceschini, Claudio Tripodo, Claudio Vernieri, Lorenzo Castagnoli
HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness. Cancers 13 (19) (2021)